DNLI - Denali Therapeutics Inc.
21.17 0.00 (0.00%)
After hours: 5:02PM EST
| Previous Close | 21.00 |
| Open | 21.00 |
| Bid | 19.50 x 900 |
| Ask | 22.00 x 800 |
| Day's Range | 20.90 - 21.38 |
| 52 Week Range | 12.32 - 25.79 |
| Volume | 227,010 |
| Avg. Volume | 410,567 |
| Market Cap | 2.01B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.78 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.00 |
- GlobeNewswire•9 days ago
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
“Based on Phase 1 data in healthy volunteer subjects demonstrating DNL747’s excellent CNS penetration, safety profile, and ability to inhibit the RIPK1 pathway, we are excited to evaluate DNL747 in ALS patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “The primary purpose of this Phase 1b study is to gain additional safety and biomarker data in ALS patients to support dose selection.
- GlobeNewswire•last month
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
“Based on the positive outcome of our Phase 1 study in 122 healthy volunteer subjects, we are excited to evaluate DNL201 in Parkinson’s disease patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “This study will provide additional important safety and biomarker data in patients to support rational dose selection.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
American City Business Journals•2 months agoHealth Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.
- Benzinga•2 months ago
The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
- American City Business Journals•2 months ago
Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
- GlobeNewswire•2 months ago
Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
SOUTH SAN FRANCISCO, Nov. 08, 2018 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- Benzinga•3 months ago
The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
- The Wall Street Journal•3 months ago
[$$] Sanofi, Denali Tie Up $1B Deal
Sanofi and Denali Therapeutics have entered a collaboration agreement valued at up to $1.02 billion to develop molecules to treat neurological and systemic inflammatory diseases.
- GlobeNewswire•3 months ago
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory.
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- American City Business Journals•3 months ago
Where Dallas’ largest hedge funds are placing their long bets
Dallas’ largest hedge funds have placed their longest bets on publicly traded companies in a variety of industries, from technology and utilities to health care and social media behemoths, according to an analysis of their most recent regulatory filings.
- Business Wire•3 months ago
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
CENTOGENE and Denali Therapeutics (DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients. CENTOGENE will conduct a targeted global recruitment campaign focused on the early identification and characterization of LRRK2 PD patients and sequence the LRRK2 gene in these patients. Under the terms of the agreement, CENTOGENE will utilize CentoCard®, its proprietary, validated, dried blood spot collection kit, to identify PD patients with a mutation in the LRRK2 gene for recruitment into Denali’s clinical trials.
- Simply Wall St.•4 months ago
Could Denali Therapeutics Inc’s (NASDAQ:DNLI) Investor Composition Impacts Your Returns?
If you want to know who really controls Denali Therapeutics Inc (NASDAQ:DNLI), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows,Read More...
- Zacks•9 months ago
Why Denali Therapeutics (DNLI) Could Shock the Market Soon
Denali Therapeutics (DNLI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
